[5] Shree, Tanaya, et al. "CD20-targeted therapy ablates de novo antibody response to vaccination but spares preestablished immunity." Blood cancer discovery 3.2 (2022): 95-102.[6] Cree, Bruce AC. "All anti-CD20 monoclonal antibodies have similar efficacy and safety risks: Yes." Multiple...
[6] Cree, Bruce AC. "All anti-CD20 monoclonal antibodies have similar efficacy and safety risks: Yes." Multiple Sclerosis Journal 28.12 (2022): 1843-1844. [7] Schuster, Stephen J.,et al."Characterization of CD20 expression loss as a mechanism of resistance to mosunetuzumab in patients wit...
These monoclonal antibodies show biological activities suitable for using as drugs.Susumu UchiyamaKiichi Fukui
In August 2019, Amgen acquired Otezla and gained the access to the company’s technology to enhance its portfolio of anti-CD20 monoclonal antibodies drugs. As a result of this acquisition, the company acquired a 35% shares responsible for the growth of global anti-CD20 monoclonal antibodies ...
2. Sellebjerg F, Blinkenberg M, Sorensen PS.Anti-CD20 Monoclonal Antibodies for Relapsing and Progressive Multiple Sclerosis.CNS Drugs. 2020 Mar;34(3):269-280.
Robak T, Robak E: New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy. 2011, 25 (1): 13-25. 10.2165/11539590-000000000-00000. Article CAS Google Scholar Jaglowski SM, Alinari L, La...
Robak T, Robak E: New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy. 2011, 25 (1): 13-25. 10.2165/11539590-000000000-00000. Article CAS Google Scholar Jaglowski SM, Alinari L, La...
As targeted drugs to B-cell malignancies, anti-CD20 monoclonal antibodies have been proved to be important in therapeutic antibody field. With three genera... DENG Chenglian,ZOU Jia,SONG Haifeng - Advances in the research of anti-CD20 therapeutic monoclonal antibodies 被引量: 10发表: 2013年 抗...
Over the last few years, new generations of anti-CD20 monoclonal antibodies (mAbs) have been developed for potential benefits over the classical, first-gen... T Robak,E Robak - 《Biodrugs Clinical Immunotherapeutics Biopharmaceuticals & Gene Therapy》 被引量: 107发表: 2011年 Ofatumumab, a seco...
16.Bornstein,G.G.et al.Development of a new fully human anti-CD20monoclonal antibody for the treatment of B-cell malignancies.Invest.New Drugs28,561-574(2010). 17.Du,J.et al.Structural basis for recognition of CD20 by therapeuticantibody Rituximab.J.Biol.Chem.282,15073-15080(2007). 18.Ni...